References
- Celebrex Summary of Product Characteristics. The electronic Medicines Compendium (eMC). Surrey, UK: Datapharm Communications Ltd, 2011. http://www.medicines.org.uk/EMC/medicine/14534/SPC/Celebrex+100mg+%26+200mg+Capsules/. Accessed July 12, 2011
- National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guidelines for care and management in adults. London, UK: Royal College of Physicians, 2008. http://www.nice.org.uk/nicemedia/live/11926/39720/39720.pdf. Accessed January 27, 2011
- National Institute for Health and Clinical Excellence (NICE). 2011. http://www.nice.com. Accessed January 27, 2011
- Latimer N, Lord J, Grant RL, et al. National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009;339:b2538
- Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–55
- Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771–81
- Kirshner H, Ruland S, Verheugt FW, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675–84
- Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665–74
- National Collaborating Centre for Chronic Conditions. Appendix D, Osteoarthritis: national clinical guidelines for care and management in adults. London: Royal College of Physicians, 2008. http://www.rcplondon.ac.uk/. Accessed January 27, 2011
- Chan FKL, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173–79
- Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–55
- Average Daily Quantities. Leeds, UK: The Information Centre for Health and Social Care, 2011. Available at: http://www.ic.nhs.uk/services/prescribing-support-unit-psu/using-the-service/reference/measures/volume-measures/average-daily-quantities-adq. Accessed July 12, 2011
- Latimer N, Lord J, O’Mahony, et al. Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors. Pharmacoeconomics 2011;29:225–37
- NHS Reference Costs 2009–2010. London, UK: Department of Health, 2011. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459. Accessed April 1, 2011
- British National Formulary (BNF), 2010. http://www.bnf.org. Accessed April 1, 2011
- Curtis L. Unit costs of health and social care. Kent, UK: Personal Social Services Research Unit (PSSRU), 2010. http://www.pssru.ac.uk/uc/uc2010contents.htm. Accessed April 1, 2011
- Hypertension: management of hypertension in adults in primary care: partial update. London, UK: National Institute for Health and Clinical Excellence (NICE), 2006. Available at: www.nice.org.uk/nicemedia/pdf/CG034NICEguideline.pdf. Accessed April 1, 2011
- Guide to the methods of technology appraisal. London, UK: National Institute for Health and Clinical Excellence (NICE), 2008. Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed July 12, 2011
- Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621–26
- Ray WA. Cardiovascular safety of NSAIDs. BMJ 2011;342:c6618